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BACKGROUND: A strategy to reduce the secondary effects of anti-cancer agents is to potentiate the therapeutic effect by their
combination. A combination of vitamin K3 (VK3) and ascorbic acid (AA) exhibited an anti-cancer synergistic effect, associated with
extracellular production of H2O2 that promoted cell death.
METHODS: The redox-silent vitamin E analogue a-tocopheryl succinate (a-TOS) was used in combination with VK3 and AA to evaluate
their effect on prostate cancer cells.
RESULTS: Prostate cancer cells were sensitive to a-TOS and VK3 treatment, but resistant to AA upto 3.2mM. When combined, a
synergistic effect was found for VK3–AA, whereas a-TOS–VK3 and a-TOS–AA combination showed an antagonist and additive
effect, respectively. However, sub-lethal doses of AA–VK3 combination combined with a sub-toxic dose of a-TOS showed to induce
efficient cell death that resembles autoschizis. Associated with this cell demise, lipid peroxidation, DNA damage, cytoskeleton
alteration, lysosomal–mitochondrial perturbation, and release of cytochrome c without caspase activation were observed. Inhibition
of lysosomal proteases did not attenuate cell death induced by the combined agents. Furthermore, cell deaths by apoptosis and
autoschizis were detected.
CONCLUSION: These finding support the emerging idea that synergistic combinations of some agents can overcome toxicity and other
side-effects associated with high doses of single drugs creating the opportunity for therapeutically relevant selectivity.
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Standard cancer therapy is plagued by undesirable adverse
side-effects, including toxicity to normal cells and evasion of
immune surveillance. These drawbacks have fuelled efforts to
develop new anti-cancer agents and additional and/or comple-
mentary strategies to inhibit cancer cell growth. These strategies
include approaches such as cancer immunotherapy (Lu et al, 2002;
Roberts et al, 2002), caloric restriction (Zhu et al, 1997); genetic
manipulation (Koch et al, 2000); a concomitant increase of the
therapeutic effect of anti-cancer drugs while reducing undesirable
secondary effects (Buc-Calderon et al, 1989); or potentiation of the
anti-tumour therapeutic effects of drugs by their combination
(Uwagawa et al, 2009; Zahorowska et al, 2009; Beauchamp et al,
2009; Eichhorn et al, 2010). Drug combination is a promising
strategy to overcome side-effects associated with high doses of
single drugs (Keith et al, 2005; Leha ´r et al, 2009).
The combined action of ascorbic acid (AA) and vitamin K3
(VK3) has been reported to synergistically induce cell death in
different cancers (De loecker et al, 1993; Verrax et al, 2005; Tareen
et al, 2008). Oxidative stress generated by the ascorbate-driven
quinone redox cycling kills tumour cells by a mechanism including
glycolysis inhibition, loss of calcium homoeostasis, DNA damage,
and altered activity of mitogen-activated protein kinases (MAPK).
In this case, cell death involves necrosis rather than apoptosis or
macroautophagy (Beck et al, 2009). Pharmacological doses of AA
(40.2mM) are required to induce oxidation-dependent cytotoxi-
city both in vitro (Beck et al, 2009) and in vivo (Tareen et al, 2008).
Cells convert ascorbate to the ascorbyl radical (A
 ) with
concomitant formation of H2O2 in extracellular fluids (Chen
et al, 2007), resulting in toxicity towards tumour cells (Rhee, 2006).
However, this approach faces a possible complications in that
the therapeutic synergy of the drug combination could be
accompanied by deleterious side-effects, and by the possibility
that the extracellular levels of H2O2 main drop below 1mM,a t
which concentration proliferation rather than cell death may be
promoted (Rhee, 2006).
To overcome these potential adverse effects, we have tested the
hypothesis that cell death induced by an extracellular oxidative
insult could be enhanced by combining apoptotic agents acting
through different modes of action. One of the emerging targets for
anti-cancer drugs is mitochondria that is central to induction of
programmed cell death (Gogvadze et al, 2008; Trachootham et al,
2009). Our previous work has identified mitochondria as transmit-
ters of apoptosis induced by the redox-silent analogue of vitamin E
(VE) a-tocopheryl succinate (a-TOS) (Neuzil et al, 2004, 2007a) that
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sis selective for cancer cells (Neuzil et al, 2001a,b) and suppresses
tumours in a variety of pre-clinical models (Neuzil et al, 2001b;
Stapelberg et al, 2005; Wang et al, 2007; Dong et al, 2008, 2009).
This suggests that the VE analogue is a promising anti-cancer drug
that may suppress tumours by causing cell death of malignant cells
as well as synergizing with other anti-cancer agents. In this study,
we used the agent in combination with VK3 and AA stimulating the
redox cycling system to evaluate their combined anti-cancer effects
on one human prostate cancer cell line.
MATERIALS AND METHODS
Cell culture and reagents
The prostate cancer cells (PC3) and fibroblasts (IMR90) purchased
from the American Type Culture Collection were grown in the
RPMI-1640 and DMEM medium, respectively, supplemented with
2m ML-glutamine, 100Uml
 1 penicillin, 100mgml
 1 streptomycin,
and 10% FBS. The cells were cultured at 371C and 5% CO2 in a
humidified incubator. AA (Sigma, St Louis, MO, USA) was
dissolved in PBS (pH 7.4) immediately before use. a-TOS and
VK3 (menadione) (both from Sigma) were dissolved in ethanol
and DMSO, respectively, diluted in complete medium to the final
concentration and added to cells at 0.1% of solvent (v/v).
Cytoxicity and isobologram analysis
PC3 and IMR90 cells were plated in 96-well flat-bottom tissue
culture plates at 10
4 per well, allowed to attach overnight and
incubated for 24, 48 and 72h with a-TOS (10–100mM), VK3 (1–
30mM), and AA (0.1–3.2mM) alone or in combination. Cell
viability was determined using the MTT assay (Carmichael et al,
1987). Briefly, after the exposure of cells, 10ml of MTT (5mgml
 1
in PBS) was added and the plate incubated at 371C for 3h. After
removing the media, 200ml of isopropanol was added and mixed
to dissolve the crystals. Absorbance was read at 550nm in an
ELISA plate reader and control absorbance was designed as 100%.
Survival curves were generated and the IC50 values determined.
The effect of combination of the drugs in PC3 and IMR90 cells was
estimated both by plotting the percentage of dead cells after
treatment with the drug alone or in combination with another drug
at its IC50 concentration and by the isobologram analysis carried
out as described in detail elsewhere (Tomasetti et al, 2004) using
the CalcuSyn1 software.
Soft agar colony-forming assay
Cells (10
4) were seeded in 24-well plates in the RPMI-1640 medium
containing 0.35% low melting point (LMP) agar, overlaid with
0.7% LMP agar, and cultured at 371Ci n5 %C O 2 for 30 days. Every
7 days, 0.5ml of fresh medium was added to each well. The
colonies of cells were treated with a-TOS (30mM), VK3–AA
mixture (3mM VK3 and 0.4mM AA), or a-TOS–VK3–AA
combination (30mM a-TOS, 3mM VK3, and 0.4mM AA), and after
7 days the colonies were stained with the crystal violet dye and
visualised by optical microscope.
Actin–phalloidine labelling
PC3 cells were placed overnight in 35-mm dishes on glass cover-
slips. After 6h of incubation with a-TOS or combinations of the
agents (VK3-AA and a-TOS–VK3–AA), the cells were washed
with PBS, fixed with 4% formaldehyde in PBS, and incubated in the
saponin solution (0.05% saponine and 2% FBS in PBS). The cells
were then incubated with TRIC-conjugated phalloidine (Sigma)
(2mgml
 1) at room temperature for 30min, and the coverslips
mounted on microscope slides with VectraShield plus DAPI
(Vector Laboratories, Burlingame, CA, USA) and inspected in a
fluorescence microscope (Zeiss, Axiocam MRc5, Thomwood, NY,
USA, magnification  60).
DNA damage
Damage of DNA was assessed using the alkaline comet assay
(Tomasetti et al, 2001). PC3, cells were placed in 96-well flat-
bottom tissue culture plate at 10
4 per well. After overnight
incubation, cells were treated with a-TOS (30mM), VK3–AA
mixture (3mM VK3 and 0.4mM AA), a-TOS–VK3–AA combina-
tion for increasing time periods, and DNA damage was evaluated.
To do so, in brief, cells were sandwiched between thin layers
of agarose on a microscope slide, lysed at alkaline pH, electro-
phoresed, stained with the DAPI dye, and inspected in the
fluorescence microscope. The number of strand breaks was scored
visually such that 100 randomly selected comets were graded
according to the degree of damage into five classes (0–4) to
provide an overall score for each gel of 0–400 arbitrary units (AU).
Oxygen consumption assay
The capacity of a-TOS, VK3, and AA alone or in combination to
induce reactive oxygen species (ROS) formation was estimated by
evaluating the oxygen consumption using the Clark’s oxygen
electrode. a-TOS (0.3mM), VK3 (30mM), and AA (4mM) were
sequentially added into the Clark’s oxygen electrode chamber and
oxygen consumption assessed.
Assessment of hydroperoxide formation
Hydroperoxide levels were evaluated in the conditioned medium
using the d-ROMs assay (Vassalle et al, 2006). PC3 cells were
placed in 96-well flat-bottom tissue culture plates at 10
4 per well.
After overnight incubation, cells were treated with a-TOS (30mM),
VK3 (3mM) AA (0.4mM) VK3–AA mixture (3mM VK3 and 0.4mM
AA), or the a-TOS–VK3–AA combination, and aliquots were
taken at different time points. Briefly, 3ml of medium was added to
the reaction mixture containing N,N-diethyl-para-phenylendi-
amine and acetate buffer (pH 4.8). Samples were subjected to 20
repeated spectrophotometric readings (520nm). The concentra-
tion was automatically calculated from the mean slope (the rate of
change in absorbance).
Assessment of generation of intracellular ROS
Intracellular ROS levels were estimated using the fluorescent dye
2070-dichlorofluorescein diacetate (DCFA). PC3 cells were seeded in
24-well flat-bottom plates and 20mM of DCFA, a cell-permeable,
ROS-sensitive dye added to each well. After 30min of incubation,
the florescent probe was removed and the cells exposed to a-TOS
(30mM) VK3 (3mM) AA (0.4mM) and vitamin combination (VK3-
AA and a-TOS–VK3–AA). After a 24-h incubation, the cells were
collected, washed, and resuspended in PBS, and analysed by flow
cytometry (FACS Calibur, Becton Dickinson, Palo Alto, CA, USA).
The level of ROS was detected as fluorescence intensity and
expressed as fold change with respect to the control.
Annexin V–propidium ioide (PI) staining
Apoptosis was quantified using the annexin V-FITC method,
which detects phosphatidyl serine (PS) externalised in the early
phases of apoptosis (Boersma et al, 1996). Cells were plated at 10
5
per well in 24-well plates. After an overnight incubation, cells were
treated with a-TOS (30mM), VK3–AA mixture (3mM VK3 and
0.4mM AA), and a-TOS–VK3–AA combination. Floating and
attached cells were collected, washed with PSBS, resuspended in
100ml binding buffer, incubated for 20min at room temperature
with 2ml annexin V-FITC, supplemented with 10ml PI (10mgml
 1),
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V-FITC binding and channel 2 for PI staining.
Western blot analysis
PC3 cells were treated with a-TOS (30mM), VK3–AA mixture (3mM
VK3 and 0.4mM AA), a-TOS–VK3–AA combination for 24h.
Floating and attached cells were collected, lysed in a buffer
containing 250mM NaCl, 25mM Tris–HCl (pH 7.5), 5mM EDTA,
1% Nonidet P-40, and a cocktail of protease inhibitors (2mgml
 1
aprotinin, 2mgml
 1 leupeptin, 1mM phenylmethyl-sulfonyl
fluoride, and 2mgml
 1 proteinin), and stored at  801C until used.
The protein levels were quantified using the Bradford assay
(Sigma). The protein samples (50mg per lane) were boiled for
5min, resolved using 12.5% SDS–PAGE, and transferred to a
nitrocellulose membrane. The membrane was blocked (PBS
containing 0.1% Tween and 5% skimmed milk) for 1h, and
incubated overnight with anti-caspase-8, anti-caspase-9, anti-
caspase-3, or anti-Bid IgG (all Cell Signaling Technology, Danvers,
MA, USA). After incubation with an HRP-conjugated secondary
IgG (Sigma), the blots were developed using the ECL detection
system (Pierce Biotechnology, Rockford, IL, USA). Band intensities
were visualised by ChemiDoc using the Quantity One software
(BioRad Laboratories, Hercules, CA, USA). b-Actin was used as a
control for protein loading.
Assessment of lysosomal and mitochondrial
destabilisation, and inhibition of lysosomes
The integrity of lysosomes and mitochondria was monitored based
on the uptake of Acridine orange (AO; Sigma) (Hopkins, 2008) and
MitoTracker Red-580 (Molecular Probes, Carlsbad, CA, USA),
respectively.
Fluorescent microscopy PC3 cells were placed in 6-well plates at
3 10
5 per well on glass coverslip. The cells were allowed to attach
overnight and then incubated 24h with a-TOS (30mM), or vitamin
combination (VK3–AA and a-TOS–VK3–AA). After treatment,
cells were resuspended in 2ml RPMI-1640 medium with 5mgml
 1
AO or 100nM MitoTracker Red-580, incubated at 371C for 15min,
mounted on slides with Vectashield (Vector Laboratories) and
viewed in a fluorescence microscope (Zeiss, Axiocam MRc5,
magnification  60).
Cytofluorimetry PC3 cells were plated overnight in a 6-well plate at
3 10
5 per well. After 24h of treatment with a-TOS (30mM)o r
vitamin combination (VK3–AA and a-TOS–VK3–AA), the cells
were incubated with 5mgml
 1 AO for 15min. Floating and attached
cells were collected, resuspended in PBS, and red fluorescence
evaluated by flow cytometry. The percentage of cells with low
intensity of red fluorescence (pale cells) was used as a marker for the
extent of lysosomal destabilisation (impairment of AO uptake).
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Figure 1 Cytotoxic effect of a-tocopheryl succinate (a-TOS), vitamin K3 (VK3), and ascorbic acid (AA) on prostate cancer cells and fibroblasts. PC3 and
IMR90 cells were seeded into 96-well tissue culture plates at 10
4 per well and treated with increasing concentration of a-TOS, VK3, and AA. The cells were
assessed for viability using the MTT assay following exposure to the agents for 24h at different concentrations (left panels) or for different times at the
concentrations shown (mM) (right panels). The IC50 values were derived from the data in the left panels. All data are expressed as mean±s.d. of the
percentage variation with respect to the control (untreated cells) of three independent experiments carried out in duplicate.
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sLysosmal inhibition Cells were incubated overnight in the
presence of 20mM E-64d, a broad-spectrum cathepsin and
calpain inhibitor, treated with a-TOS or vitamin combi-
nation (VK3-AA and a-TOS-VK3- AA) for 24h, and assessed for
viability, mitochondrial and lysosomel integrity, and cytochrome
c release.
Cytochrome c release
PC3 cells (3 10
5 per well in 6-well plates) were treated with a-TOS
or vitamin combination (VK3–AA and a-TOS–VK3–AA) for 24h.
Cells were then harvested and the pellet resuspended in the
digitonin cell permebilization buffer. After incubation on ice
for 5min, the cells were centrifuged at 1000g for 5min at 41C.
The supernatant containing the cytosolic fraction of cytochrome
c was collected. The remaining pellet was resuspended in the RIPA
cell lysis buffer, vortexed, and incubated on ice for 30min. The
lysate was then centrifuged at 10000g for 10min at 41C. The
cytosolic and mitochondrial fractions were then assessed using the
enzyme immunometric assay kit (Assay Designs, Hines Drive Ann
Arbor, MI, USA). The results were quantified as pgml
 1 and
expressed as percentage of cytochrome c in each fraction respect to
the total.
Statistical analysis
Data are presented as mean±s.d. Comparisons between groups
were carried out using the Mann–Whitney U-test for unpaired
samples and Kruskall–Wallis analysis for multiple comparisons.
Statistical calculations were carried out using the SPSS statistical
package version 12.0F. Statistical differences of at least Po0.05
were considered statistically significant.
RESULTS
aTOS, VK3, and AA exert different toxicity towards
prostate cancer cells and fibroblasts
Treatment of PC3 cells with a-TOS and VK3 resulted in dose-
dependent cytotoxicity, whereas the cells were completely resistant
to AA. Figure 1 (left panel) shows the viability curves of PC3 cells
with IC50 value ranging from 30 to 40mM for a-TOS and 4–5mM for
VK3. The cells were completely resistant to AA treatment up to
3.2mM, exerting its cytotoxic effect at prolonged exposure times
(Figure 1, right panel). The dose- and time-dependent plots show
that low doses of a-TOS and AA were not cytotoxic within the
initial 24h of drug exposure, whereas cell death was observed at
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Figure 2 Induction of cell death in prostate cancer cells exposed to a-tocopheryl succinate (a-TOS) in combination with vitamin K3 (VK3) and ascorbic
acid (AA). The effect of a-TOS, VK3, and AA on prostate cancer cells was evaluated on the basis of cell death induced by the drugs alone or in combination
(left panels). Synergistic, additive or antagonistic effects of sets of two drugs were assessed by constructing the isobolograms at IC50 based on the results of
the MTT assay for PC3 cells treated with individual combinations of two drugs. Each isobologram combines the results of at least three independent
experiments carried out in duplicate.
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Figure 3 Effect of a-tocopheryl succinate (a-TOS) alone or in combination with the vitamin K3 (VK3) and ascorbic acid (AA) on cell-death induction and
viability of prostate cancer cells and fibroblasts. (A) PC3 and (B) IMR90 cells were exposed to a sub-apoptotic dose of a-TOS (30mM) alone or in
combination with sub-apoptotic levels of VK3 (3mM) plus AA (0.4mM). The cells were then assessed for cell death and viability. The results are expressed as
mean±s.d. of percentage and of the percentage variation with respect to the control (untreated cells) of three independent experiments carried out in
duplicate.
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Figure 4 Morphological changes of prostate cancer cells exposed to a-tocopheryl succinate (a-TOS) and vitamin K3 (VK3) plus ascorbic acid (AA) alone
or in combination. (A) For the soft-agar colony-forming assay, cells were seeded in 24-well culture plates at 10
4 per well in the RPMI-1640 medium
containing 0.35% low melting point (LMP) agarose overlaid with 0.7% LMP agarose. The cells were maintained at 371Ci n5 %C O 2 for 30 days; every 7 days,
500ml of fresh medium was added to each well. The formed colonies were treated with a sub-lethal dose of a-TOS (30mM) or VK3 (3mM) plus AA (0.4mM),
or the three drugs at these doses together, and the cells were stained with crystal violet after 7 days and inspected by optical microscope. (B) PC3 cells were
placed overnight in 35-mm dishes on glass coverslips. After a 6-h incubation with a-TOS (30mM) or VK3 (3mM) plus AA (0.4mM), or the three drugs at these
concentrations together, the cells were stained with phalloidine–TRIC, and the coverslips mounted on microscope slides with Vectrashield containing DAPI
and inspected in a fluorescence microscope.
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sprolonged time points. No effect of VK3 below 3mM occurred. It
should be noted that non-malignant cells such as fibroblasts were
resistant to a-TOS and AA at concentrations up to 100mM and
3.2mM, respectively. VK3 was found toxic for the IMR90
fibroblasts at concentrations over 10mM.
Effect of the combination of a-TOS, VK3, and AA on
prostate cancer cells
To study the combined effects of a-TOS, VK3, and AA, PC3 cells
were exposed to increasing concentrations of individual drugs
alone or in combination, and cell death was assessed. The data
were then used to carry out isobologram analysis. The IC50 values
for one drug o1 were plotted against corresponding IC50 values
for the other drug. Distribution of individual points along the
diagonal connecting the values of 1 suggests an additive effect of
the two drugs, whereas the points below or above the line indicate
their synergism and antagonism, respectively (Figure 2, right
panel).
Antagonistic effects on cell death induction were found for the
combination of a-TOS and VK3, and the presence of a-TOS
markedly reduced VK3-induced cell death (Figure 2, left
panel). No cytotoxic interaction was observed for the a-TOS–AA
combination, whereas a synergistic effect was found for the
VK3–AA combination. The cytotoxic effect of VK3 was
synergistically enhanced by the addition of increasing doses of
AA (Figure 2).
aTOS and VK3–AA in combination exert selective
cooperative effect in prostate cancer cells
The effect of a-TOS on cytotoxicity induced by the combination of
VK3 and AA was evaluated using the PC3 prostate cancer cells and
the IMR90 fibroblasts. Cell death induced by the VK3–AA
combination was found to be enhanced by a-TOS, and the effect
was synergistic/additive (Figure 3A). Combining sub-lethal dose of
a-TOS with a VK3 plus AA that alone does not induce cell death
caused induction of cell death in PC3 cells after 24h of exposure to
the agents. This effect was selective for the cancer cells, as no cell
death was observed when the combination of the three compounds
was used to challenge the non-malignant fibroblasts (Figure 3B).
We then verified the morphological changes of PC3 cells treated
with the agents alone or in combination. The efficacy of a-TOS to
induce cell damage in combination with VK3 plus AA was first
evaluated in vitro using the soft-agar colony-forming assay. As
shown in Figure 4A, PC3 cells gave rise to numerous and large
colonies in soft agar. The colonies were then treated with the drugs
alone or in combination. Translucent and pycnotic cells were
observed after 1 week of incubation when the agents were added
together.
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Figure 5 Reactive oxygen species (ROS) generation and DNA fragmentation induced in prostate cancer cells by a-tocopheryl succinate (a-TOS) or
vitamin K3 (VK3) plus ascorbic acid (AA) alone or in combination. (A) The capacity of a-TOS or VK3 plus AA alone or in combination to induce ROS
formation was evaluated by assessing the oxygen consumption using the Clark’s oxygen electrode. (B) PC3 cells were placed in 96-well flat-bottom tissue
culture plate at 10
4 per well. After overnight incubation, cells were treated with a-TOS (30mM), VK3 (3mM), and AA (0.4mM) alone or in combination, and
aliquots of the conditions media were taken at regular intervals and evaluated for the level of hydroperoxides using the d-ROMs assay. Data are expressed as
of percentage variation with respect to the control. (C) Intracellular ROS were estimated using the fluorescent dye 2070-dichlorofluorescein diacetate
(DCFA). PC3 cells were seeded in 24-well flat-bottom plates and 20mM of DCFA added. After 30min of incubation, the cells were exposed to a-TOS
(30mM), VK3 (3mM), and AA (0.4mM) alone or in combination. After 24h, the cells were evaluated by flow cytometry. The amount of ROS was detected as
fluorescence intensity normalised for the blank (samples without DCFA) and expressed as fold change with respect to the control (untreated cells). (D)
DNA fragmentation was analysed using the alkaline comet assay. PC3 cells were seeded in 96-well flat-bottom tissue culture plates at 10
4 per well, treated
after overnight incubation with a-TOS (30mM), VK3 (3mM), and AA (0.4mM) alone or in combination, and evaluated for DNA damage at different time
points. The level of DNA strand breaks was assessed using the comet assay that is based on visual scoring with the maximum of 400 arbitrary units (see
Material and Methods for detail). The data are expressed as the percentage variation with respect to the control (untreated cells).
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sPhalloidin staining for actin was used to assess the effect of
treatment with a-TOS, VK3–AA, and a-TOS in combination with
VK3 plus AA on morphology of the cells. After 6-h exposure, cells
treated with the combination of the three agents underwent
morphological alterations such as formation of cytoplasmic blebs
(Figure 4B). These blebs are associated with the preservation and
diminution of cell size and suggest that those cells loose pieces
through a mechanism of self-excision. Further, the treated cells
display a pleiomorphism that makes them elongated, enormous, or
smaller than the control tumour cells. The nuclei of the treated
cells are not showing condensations typical of apoptotic stages and
are enlarged. They also appear with an enhanced inner envelope
with excessive phalloidin contrast and show enlarged nucleoli.
Nuclei remain unbroken and are not part of the pieces shed by the
cells as it would be in apoptotic bodies. Hence, the cell demise
appears to demonstrate the characteristics of autoschizis cell death
as previously described (Gilloteaux et al, 1998, 2001, 2005).
a-TOS and VK3 plus AA cause generation of ROS
The ability of a-TOS, VK3, and AA, and their combination to
induce ROS formation has been assessed using the Clark’s oxygen
electrode. The agents were sequentially added into the oxygen
electrode chamber and consumption of oxygen evaluated. As
shown in Figure 5A, VK3 itself did not induce oxygen consump-
tion, which was observed to occur following the addition of AA.
Similarly, no oxygen consumption occurred both in the presence
of a-TOS and VK3, whereas it was observed in the presence of AA.
We next tested generation of ROS induced by incubation of PC3
cells with sub-apoptotic doses of the three agents alone or in
combination. The presence of extracellular ROS has been evaluated
by the determination of hydroperoxide levels in the conditioned
medium of the treated PC3 cells. The levels of ROS were found to
increase after 1h of incubation with VK3 plus AA in the presence
of a-TOS (Figure 5B). It should be noted that a-TOS itself was
responsible for the observed induction of intracellular ROS
formation, whereas VK3 plus AA did not increase the intracellular
ROS production any further (Figure 5C).
The efficacy of the three agents to induce DNA damage, which
was assessed as single strand break (SSB) formation (Figure 5D),
was evaluated. VK3 plus AA induced generation of SSBs, which
was observed after a 1-h treatment. SSBs induced by VK3 and AA
were not repaired and persisted in the cells for up to 24h. It is
interesting to note that a-TOS did not increase the SSB formation
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Figure 6 Effect of a-tocopheryl succinate (a-TOS) or vitamin K3 (VK3) plus ascorbic acid (AA) alone or in combination on the cell death induction and
destabilisation of mitochondria and lysosomes. PC3 cells were exposed for 24h to sub-apoptotic level of a-TOS (30mM) or VK3 (3mM) plus AA (0.4mM)
alone or in combination, and cell death evaluated by the (A) annexin V-propidium ioide staining and (B) caspase activation. Lysosomal destabilisation in cells
treated as described above was evaluated by the uptake of (C) Acridine orange (AO), (D) mitochondrial perturbation was assessed by cytochrome c
release. The sign ‘*’ denotes significantly different data for treated and control cells with Po0.05.
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sobserved when the cells were exposed to VK3 plus AA, neither did
it affect the DNA repair.
Combination of aTOS, VK3, and AA induces cell death by
lysosomal and mitochondrial destabilisation
Incubation of PC3 cells with a combination of aTOS, VK3, and
AA at a dose at which the individual compounds alone do not
induce cell death was found to cause detachment of cells (data
not shown) and phosphotidylserine externalisation (Figure 6A).
Typically, 50–60% cells were annexin-V positive. However, no PI
uptake (data not shown) and no sign of caspase activation
(Figure 6B) were observed. We therefore investigated the potential
role of the lysosomal/endosomal system, which has a major role in
intracellular protein degradation and recycling, as it has been
suggested to promote cell death, as shown, for example, for a-TOS
(Neuzil et al, 1999, 2002). Therefore, a possible release of
lysosomal proteases and mitochondrial cytochrome c to the
cytosol have been tested in PC3 cells exposed to a-TOS or VK3
plus AA, as well as to a-TOS with VK3 plus AA. Some 50–60% pale
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Figure 7 Induction of apoptosis by a-tocopheryl succinate (a-TOS) or vitamin K3 (VK3) plus ascorbic acid (AA) alone or in combination in the presence
of a lysosomal protease inhibitor. PC3 cells were exposed for 24h to sub-apoptotic doses of a-TOS (30mM) or VK3 (3mM) plus AA (0.4mM) alone or in
combination, and (A) lysosmal and (B) mitochondrial destabilisation were evaluated using the Acridine orange (AO) and MitoTracker Red-580 staining,
respectively, in the presence or absence of the lysosomal protease inhibitor E-64d. (C) Cytochrome c release and cell viability after treatments of prostate
cancer cells as described above in the presence or absence of lysosomal protease inhibitor E-64d was assessed. The sign ‘*’ denotes significantly different
data for treated and control cells with Po0.05.
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scells (Figure 6C) and cytochrome c release (Figure 6D) were
observed in cells treated with the combination of a-TOS, VK3, and
AA. Control cells exhibited a punctuated red fluorescence pattern
of AO and MitoTracker Red-580, suggesting that the two dyes
accumulated in lysosomes and mitochondria, respectively (Figure
7A and B, upper panel). The combination of a-TOS, VK3, and AA
caused appearance of cells with substantially decreased red
fluorescence due to the loss of lysosomal and mitochondria
integrity. Pre-treatment of cells with E-64d reduced neither
lysosomal damage nor mitochondrial permeabilisation (Figure
7A and B, lower panel), coinciding with the appearance of
cytochrome c in the cytosol (Figure 7C) and cell death induction
(Figure 7D).
DISCUSSION
Selective therapy for neoplastic pathologies has not been found thus
far, which presents a major obstacle in efficient cancer management
(Hopkins, 2008). Cancer treatment requires modulation of con-
crete targets, which can be compromised by the compensatory
mechanisms and/or mutations (Stelling et al, 2004; Kitano, 2007).
Overcoming these problems often requires high drug doses that
may, on the other hand, promote deleterious effects to non-
cancerous tissues (Kassouf et al,2 0 0 5 ) .C o m b i n a t i o n so ft w oo r
more agents that exert a synergistic effect can overcome the
undesirable toxicity and other side-effects associated with high
doses of single drugs, allowing a reduced dosage of each compound.
We therefore tested exposure of prostate cancer cells to three
agents, a-TOS, VK3, and AA, widely studied as anti-cancer
compounds, alone or in combination (Chen et al, 2005; Ogawa
et al, 2007; Neuzil et al, 2007b). a-TOS and VK3 were both highly
cytotoxic towards prostate cancer cells, whereas lethal effects
of AA were observed only at prolonged times of exposure (c.f.
Figure 1). An antagonistic interaction was found for the
combination of a-TOS and VK3, whereas AA did not exert any
effect when combined with a-TOS. As previously described
(De Loecker et al, 1993; Jamison et al, 1996; Verrax et al, 2005;
Tareen et al, 2008; Beck et al, 2009) and also observed in this study,
an efficient synergistic effect on cell viability was observed for the
pro-oxidant mixture containing pharmacological doses of AA and
a redox-active compound such as menadione (VK3), (c.f. Figure 2).
Indeed, the combination of AA and the redox-cycling quinone VK3
promotes oxidative stress that may kill cancer cells (Taper and
Roberfroid, 1992; Taper et al, 2001). Oral administration of the
VK3–AA mixture in the ratio 1:100 (the Apatone preparation)
significantly increased the mean survival time of nude mice
inoculated i.p. with the DU145 prostate cancer cells and
significantly reduced the growth rate of solid tumours without
inducing any significant bone marrow toxicity and pathological
changes of non-tumour tissues (Jamison et al, 2005). Further,
the safety and efficacy of oral Apatone supplementation were
demonstrated in patients with prostate cancer resilient to standard
therapy (Tareen et al, 2008). However, the potential long-term
effect of Apatone on the disease progression and possible secondary
side-effects are not known and remain to be investigated.
To reduce the pharmacological doses of the agents, we
combined VK3 plus AA at concentrations that themselves do not
induce apoptosis with sub-apoptotic levels of a-TOS. This
combination of the three drugs was efficient in induction of cell
death in a selective manner that appears to be as autoschizis cell
death (c.f. Figures 3 and 4). The soft-agar colony-forming assay
was carried out to mimic the in vivo situation, where tumour cells
grow as masses. Soft-agar assay and phalloidin staining of actin
have been employed to reveal a potential effect of the treatment
with a-TOS, VK3, and AA, and with VK3–AA–a-TOS on the
morphology of the cells. PC3 cells exposed to the combination
of VK3, AA and a-TOS displayed blebs and membrane alterations
related to cytoskeleton changes (c.f. Figure 4). The cells also
significantly decreased their size and changed their shape similarly
to those found after a combined VK3–AA treatment (Gilloteaux
et al, 2005). The specificity of the anti-tumour activity of VK3 plus
AA is related to their ability to induce ROS formation (Venugopal
et al, 1996). We observed oxygen consumption only in the
presence of both VK3 and AA. Although the sub-apoptotic dose of
the combination of VK3 with AA resulted in the appearance of
hydroperoxides in the extracellular compartment, intracellular
generation of ROS and persistent DNA damage, the cells died only
in the presence of a-TOS (c.f. Figure 5). We observed that cell
death in cells treated with the combination of a-TOS, VK3, and AA
proceeded without caspases activation (c.f. Figure 6). A caspase-3
independent cell death was previously observed in leukaemia
cells after VK3–AA treatment (Verrax et al, 2005). This can be
reconciled with the notion that peroxidation of the plasma
membrane of cells may favour unregulated increase in intracellular
levels of calcium as previously observed (Sakagami and Satoh,
1997), which, along with thiol oxidation, may result in mitochon-
drial destabilisation.
Mitochondria has recently emerged as the effective target for
anti-cancer drugs (Fantin and Leder, 2006; Gogvadze et al, 2008).
a-TOS, a compound epitomising the ‘mitocan’ group of anti-
cancer agents (Neuzil et al, 2007a), was found to induce cell death
by generation of superoxide anion radicals by targeting complex II
of the mitochondria respiratory chain (Dong et al, 2008, 2009).
ROS, in turn, promote apoptosis by catalysing the formation of
disulfite bridges between monomeric Bax, resulting in the
formation of mitochondrial outer membrane channel. ROS also
cause oxidation of cardiolipin, triggering the release of cytochrome
c and its translocation through the Bax channel (d’Alessio et al,
2005; Neuzil et al, 2006). Mitochondrial channel in response to
a-TOS can also be formed by transcriptional upregulation of Noxa,
which results in formation of Bak oligomeric structures (Neuzil
et al, submitted).
In addition, ROS cause destabilisation of lysosomes, presumably
leading to cytosolic translocation of various proteases (Neuzil
et al, 1999, 2002). Lysosomal destabilisation as well as cytosolic
release of cytochrome c were observed in cells exposed to a-TOS
in combination with VK3 plus AA. It was shown earlier that
perturbation of lysosomes results in cell death, mostly by auto-
schizis that is dependant on mitochondria (Boya et al,2 0 0 3 ) .W e
observed in this study that the inhibitor of lysosomal destabilisation
did not attenuate mitochondrial ‘leakage’, leading to cytochrome c
release, and subsequent cell death (c.f. Figures 6 and 7). This
reinforces the concept that mitochondrial destabilisation constitutes
a central event in the programmed cell death such as apoptosis and
autoschizis (Verrax et al, 2005). Again, this evokes the possibility
that primary thiol oxidation of mitochondrial proteins, derived
from an oxidative shift in the cellular redox potential (Venugopal
et al, 1996), can induce mitochondrial membrane permeabi-
lisation (Zamzami et al, 1998). Moreover, oxidation of critical
thiols within the catalytic centre of caspases annihilates their latent
proteolytic potential and, thus, preclude their auto-activation
(Mannick et al,2 0 0 1 ) .
We conclude that a-TOS synergistically cooperates with VK3
plus AA in the induction of prostate cancer cell apoptosis. The
combination of VK3, AA, and a-TOS induces cell death that is
selective for cancer cells and proceeds through a caspase-
independent pathway. We propose that addition of a-TOS at
sub-apoptotic doses may be considered for cancer therapy when
high doses of established drugs are required.
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